A few months ago I blogged that Pops had taken the bold step of jumping on Twitter and actually tweeting (that's Twitter-speak for sending out messages of 140 characters or less.) Well, now, a sell-side biotech analyst is tweeting, too.
Ray Elliott put in less than six months on the job last year at Boston Scientific as the medical device maker's new CEO. But, according to "The New York Times," in that short amount of time Elliott received enough total compensation to make him the second-highest paid head honcho behind only Oracle's Larry Ellison (albeit a distant #2.)
Former chairman of the Federal Reserve Alan Greenspan reinforced increasingly confident assessments by the Obama administration that the nation’s latest job numbers reveal a resurgent economy.
FDA advisory committee votes sometimes end in confusion. First, because the actual vote often gets all convoluted and recounted as some panelists hem and haw about voting thumbs up or thumbs down and try to equivocate their decision. And second, because no matter how many times I've explained it to people here, the votes get misread and miscommunicated as actual approval or rejection of a drug versus a recommendation that the FDA clear or spike a drug.
The world’s largest drug company, Pfizer, has handled mergers badly, invented too few drugs and left its reputation in disrepair after two criminal cases. And that is the assessment of its own chief executive. The NYT talks to Pfizer CEO Jeffrey Kindler.
But, oh! The irony. At a meeting designed to convince the Street the company is well on its way to correcting a major manufacturing problem, a simple technical glitch keeps executives from conveying that message to a broader, off-site audience.
A federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property. The NYT reports.
More than a week after President Obama signed the sweeping new health care law, which will eventually provide insurance coverage for 32 million uninsured Americans, many of us are still scratching our heads. What just happened? And how and when will we start feeling its effect? the NYT explains.
Electronic health records are a good first step, but represent only one aspect of how IT can improve America’s healthcare system by making it seamless and safer, writes Chris Begley, Chairman & CEO, Hospira, Inc.
You need to buy the paper edition for $5 or subscribe to the website to see it for yourself, but Barron's has put only one biopharma honcho on its annual list of the world's top-30 CEOs.
Vivus announced this morning that an FDA advisory committee is tentatively scheduled to take a look at its diet drug Qnexa on Thursday, July 15th.
One of the many things I think is great about Twitter is the direct contact it gives me with a handful of biopharma reporters who are using it.
Carl Icahn, reputed to be a late-riser, woke up to good news and bad news today.
Shares of Teva Pharmaceutical Industries are once again trading at an historic high. But they might not be there today if it weren’t for a tragedy.
Hospitals and drug makers, which supported the final healthcare legislation, would be clear beneficiaries, analysts say, even if the outlook for insurers was less certain, the NY Times reports.
The 800-pound gorilla of one industry has beaten the 800-pound gorilla of another. Teva CEO Shlomo Yanai took on Pfizer CEO Jeff Kindler and won.
Take our quiz and see how much you know about products that were recalled to keep consumers safe.
Speaker Pelosi is as good as it gets in wrestling votes for legislation she favors. She is the female version of that titan, Tip O'Neill (D. Mass.) who famously said, "All politics is local." But as good as she is, the Speaker seems to have come up short with the necessary votes to get the Senate version of the health care bill passed in the House of Representatives.
I can hear the commercial now. “Underarm protection that literally makes you feel more like a man.”
With states squeezing payments to providers even as the economy fuels explosive growth in enrollment, patients are finding it increasingly difficult to locate doctors and dentists who will accept Medicaid coverage. The New York Times reports.